Phase II Study of KRP-AB1102

A Phase II, Randomized, Double-blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of KRP-AB1102 Compared With Placebo for 4- Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221867

Enrollment

360

Registered

2012-07-27

Start date

2012-07-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD

Interventions

investigational material(s) Generic name etc : KRP-AB1102 INN of investigational material : Therapeutic category code : 229 Other agents affecting respiratory organs Dosage and Administration for Inv

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adult male or female COPD patients aged >40, and others.

Exclusion criteria

Exclusion criteria: - History or current diagnosis of asthma. - Patient hospitalized for an acute COPD exacerbation within 3 months prior to screening visit, and others.

Design outcomes

Primary

Measure	Time frame
Trough FEV1 The change from baseline in trough FEV1	—

Secondary

Measure	Time frame
Health related QOL scores, and others. TDI, SGRQ, and others.	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026